ASH 2023
Novel science and breakthroughs presented at the 65th ASH Annual Meeting and Exposition, taking place December 9-12, 2023, in San Diego, California.
Researchers sought to describe the clinical and sociodemographic characteristics of AYA patients with CLL.
Patients who received CLL/SLL-directed therapies had a lower risk of Richter transformation.
The prevalence of BTK C481 mutations might be higher in CLL patients with longer BTKi exposure.
Venetoclax induces a distinct and prominent transcriptional response in patients with chronic lymphocytic leukemia.
Advertisement
Advertisement